Navigation Links
DiObex in Medical Technology

DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia

...poglycemia in diabetes patients. The patent grants diobex exclusive rights to methods of reducing the risk o...s. In addition to the recently issued U.S. patent, diobex owns seven U.S. patent applications and 30 corresp...g foreign patent applications relating to DIO-901. diobex also owns or has exclusively licensed seven U.S. p...

DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug

...ditional indications under evaluation for DIO-902, diobex is well positioned to move a strong pipeline of pr...d more effective than racemic ketoconazole. About diobex DiObex, Inc. is a San Francisco-based biotechnolo... products for the treatment of metabolic diseases. diobex has two product candidates in Phase 2 clinical dev...

Diobex Announces Successful Completion of Phase 2a Trial Of DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes

...citing new drug category," commented Daniel Green, diobex President. "DIO-902 offers the possibility of ad..., M.D., Vice President of Development at DiObex. diobex plans on initiating a 16-week phase 2b dose-ranging study with DIO- 902 in mid 2007. About diobex DiObex, Inc. is a San Francisco-based biopharmac...

DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

...ations normalized during the two week treatment. diobex will conduct a multi-center, 16-week, phase 2b dos...g patients in three countries in mid-2007. About diobex DiObex, Inc. is a San Francisco-based biopharmac... products for the treatment of metabolic diseases. diobex has two products preparing to enter Phase 2b clini...
DiObex in Biological Technology

DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics

...2 is an oral, single enantiomer of ketoconazole, a common anti-fungal drug. diobex is developing DIO-902 as a novel cortisol inhibitor for treating type 2 dia...logy company developing novel products for diabetes and metabolic diseases. diobex has two product candidates in four mid-stage clinical development programs....

DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology

...ANCISCO and LUND, Sweden, March 18 /PRNewswire/ -- diobex and Camurus announced today that they have signed ...ality of life to coma and death," said David Cory, diobex CEO. "This license agreement and development progr...in-induced hypoglycemia in patients with diabetes. diobex has successfully completed three Phase 1 proof-of-...

DiObex, Inc. to Present at Merrill Lynch Global Healthcare Conference

...te presentation at the upcoming Merrill Lynch & Co, Inc. Global Pharmaceutical, Biotechnology and Medical Device Conference in New York, New York. The diobex presentation will take place on Wednesday, Feb. 6 at 10:20 a.m. at the Grand Hyatt Hotel in the Broadway room. About DiObex DiObex, Inc. is a priv...

DiObex Inc. to Present at BIO Mid-America Venture Forum

...y, September 26th at 1:30 p.m. at the Hyatt Regency Hotel in Room A. About diobex DiObex, Inc. is a San Francisco-based biotechnology company founded to develop novel products for the treatment of metabolic diseases. diobex has two product candidates in Phase 2 clinical development. DIO-901 (very l...
Other Tags
(Date:1/22/2015)... (PRWEB) January 23, 2015 AngelWeddingDress, the ... of 2015 maternity wedding dresses. View website ... are looking for maternity wedding dresses online for a ... gowns with high quality for them. Its maternity wedding ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in this market ... applications. Chemical sensors help in recording of patient data ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... systems. Multimodal biometric systems utilize more than one characteristic ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
Other Contents